Profile – A/Prof Marcel Nold

Centres > The Ritchie Centre > Scientists and Staff > A/Prof Marcel Nold

A/Professor Marcel F Nold M.D.

marcel_nold

 

Research Group Head, Interventional Immunology in Neonatal Diseases and Beyond
Alumnus Monash University Larkins Fellow
Fielding Foundation Fellow, Hudson Institute
email: marcel.nold@monash.edu

 

Marcel is a clinician-scientist, paediatrician and neonatologist, alumnus Larkins Fellow of Monash University and current Star Recruitment Fellow of MIMR-PHI Institute of Medical Research. After his graduation from medical school in 2000, he trained in paediatrics and basic immunology in Frankfurt, Germany. In 2006, he was awarded a competitive fellowship by the DFG, the German NHMRC-equivalent, to undertake a postdoctoral tenure at the laboratory of Charles Dinarello, one of the founding fathers of cytokine biology, in Denver, CO, USA. Some of his achievements of this productive time included the description of anti-viral and angiogenic properties of interleukin (IL-)32 (papers #4 and 5 below), and the important paper on the functional differences between monocytes and macrophages (#6 below, 200+ citations).

In 2009, Marcel and his wife Claudia were invited to lead a laboratory at the Ritchie Centre / MIMR-PHI in Melbourne, and to continue his medical training at Monash Newborn. On the clinical side, he received his board certifications in paediatrics in 2010 and in neonatology in 2012. In science, Claudia, Marcel and their team continued to publish at a very high level, with two accomplishments standing out: they revealed the powerful anti-inflammatory properties of IL-37 (#2 below), a landmark discovery whose impact is illustrated by 80+ citations, the consecutive renaming of the IL-1 family of cytokines (#3 below) the German Society of Immunology’s prestigious Georges Köhler Prize, enthusiastic praise by the Faculty of 1000 and national and international TV and radio coverage. The second achievement exemplifies the translational trajectory that is paramount at their laboratory: the Nolds have almost completed the bedside-to-bench-and-back circuit with their work on interleukin 1 receptor antagonist (IL-1Ra) in bronchopulmonary dysplasia (BPD). As Marcel had experienced the urgent medical need to find the first safe and effective treatment for BPD in the neonatal intensive care unit, the Nolds showed in a mouse model that IL-1Ra prevents the disease (#1 below). They are now planning a clinical trial to prove the concept in babies. Because of these innovative programs, Claudia and Marcel have been awarded substantial grant funding and an international patent, and are collaborating with partners in the pharmaceutical industry.

Selected Publications:

1. Nold-Petry CA, Lo CY, Rudloff I, Elgass KD, Li S, Gantier MP, Lotz-Havla AS, Gersting SW, Cho SX, Lao JC, Ellisdon AM, Rotter B, Azam T, Mangan NE, Rossello FJ, Whisstock JC, Bufler P, Garlanda C, Mantovani A, Dinarello CA, Nold MF. IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol, March 2015

Publication link: http://www.ncbi.nlm.nih.gov/pubmed/25729923

2. Nold MF, Mangan NE, Rudloff I, Cho SX, Shariatian N, Samarasinghe TD, Skuza EM,Veldman A, Berger PJ, Nold-Petry, CA. Interleukin 1 receptor antagonist prevents murine BPD induced by perinatal inflammation and hyperoxia. PNAS 2013, 110(35):14384-89.

3. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010, 11(11):1014-22.

4. Dinarello CA, […] Nold MF et al. IL-1 family nomenclature. Nat Immunol 2010, 11(11):973.

5. Nold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, Farkas L, Cho SX, Zepp JA, Azam T, Dinkel H, Palmer BE, Boisvert WA, Cool CD, Taraseviciene-Stewart L, Heinhuis B, Joosten LA, Dinarello CA, Voelkel NF, Nold MF. IL-32 promotes angiogenesis. J Immunol 2014, 192(2):589-602.

6. Zepp JA, Nold-Petry CA, Dinarello CA, Nold MF. Protection from RNA- and DNA-viruses by IL-32. J Immunol 2011, 186(7):4110-8. [featured among 10% best papers in the issue]

7. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, van de Veerdonk FL, Ferwerda G, Heinhuis B, Devesa I, Funk CJ, Mason RJ, Kullberg BJ, Rubartelli A, van der Meer JW, Dinarello CA. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009, 113(10):2324-35.